More from the Company Monthly Newsletter June 2018

During the month of June, we held an extraordinary general meeting, participated at the Småbolagsdagen in Stockholm and the 3rd Annual Clinical Trial Supply Conference in Copenhagen,  presented the financial agreement and conducted face-to-face meetings with a number of potential distributors.

We started the month with an extraordinary general meeting. Approximately two weeks thereafter, we announced that we had entered into a financing agreement with European High Growth Opportunities Securitization Fund through its financial advisor Alpha Blue Ocean Inc., regarding a financing solution based on the issuance of convertible bonds with warrants attached. The financing solution means that the Company is able, over a 18-month period, to receive SEK 14.0 M. The Company can receive an additional SEK 12 M if desired, and potentially up to an additional SEK 7.8 M, if all the warrants issued are exercised.
QuickCool has entered into the financing agreement in order to secure the Company's financing. The financing will provide capital to QuickCool over the next 18 months and finance the finalization of the Company’s CE-mark activities, as well as the production start and market launch.
I appreciate the personal discussions with shareholders who phoned in order to enhance the understanding of the financial solution, and appreciate your continued confidence and support.

The work towards the CE-mark progresses. A lot of testing was conducted and documentation was updated during the month.

We participated in the 3rdAnnual Clinical Trial Supply Conference in Copenhagen in order to potentially find partners who can assist in forthcoming as well as future clinical trials and studies.

Aktiespararna arranged Småbolagsdagen in Stockholm. We were situated just at the entrance of the event, resulting in many spontaneous visits and a good opportunity to talk with shareholders. There were more than 320 visitors and another 3 700 persons who participated via Internet during the day.

QuickCool’s presentation (only in Swedish) from Småbolagsdagen is available by clicking on the following link:

We finished the week with a number of face-to-face meetings with potential distributors in Europe. We trust and hope that we will have reason to share additional information from these meetings in the future.

Everyone at QuickCool would like to seize the opportunity of wishing you a nice and sunny summer!

Please visit our homepage for additional information about our QuickCool©SYSTEM:

Kind regards,

Fredrik Radencrantz

QuickCool AB 
Ideon Science Park
Beta 6, Scheelevägen 17 - SE-223 70 Lund - Sweden
E-mail: Web:
Mobile +46 (0)73 834 1188

Quickcool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the Quickcool SYSTEM. Quickcool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. Quickcool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to



Documents & Links